Pharmaceutical and healthcare report offering, “Bronchitis – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global bronchitis market. The report identifies the key trends shaping and driving the global bronchitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global bronchitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.The global bronchitis market was valued at $482m in 2009 and is forecast to grow by 3.7% annually for the next seven years. The typical form of bronchitis is self-limited. The bronchitis market is characterized by many generics and OTC. The NSAIDS, cough suppressants and antipyretics are mere supportive therapies. Antibiotics are highly prescribed to treat atypical form of the disease. The increase in the market size is attributed to the increase in incidence and increase in the up take of cost effective drugs

There are 13 molecules in the various phases of the developmental pipeline. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The antibiotics in the pipeline are generic. Upon approval they will add to the competition. The phase of the pipeline consists of levefloxacin and Merck’s Singulair. Upon approval they are expected to intensify the competition

Scope

The scope of the report includes:

• Annualized global bronchitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report are the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include alpha 1 adrenergic receptors agonist, beta (2)-adrenergic agonist,, anti-inflammatory, inhibitor topoisomerase IV DNA gyrase, glucocorticoid agonist leukotriene D4 antagonist and loop diuretic
• Analysis of the current and future market competition in the global bronchitis market. The key market players covered are Merck and Co and Johnson & Johnson Pharmaceutical Research & Development, Pfizer and Merck & Co.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future bronchitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global bronchitis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global bronchitis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global bronchitis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Merck & Co., Inc
Pfizer Inc.
Abbott Laboratories
Johnson & Johnson

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3185/Bronchitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report,” Allergic Conjunctivitis – Drug Pipeline Analysis and Market Forecasts to 2016” provides essential source of information and analysis on the global allergic conjunctivitis market. The report identifies the key trends shaping and driving the global allergic conjunctivitis market. The report also provides insights into the prevalent competitive landscape and the companies expected to significantly alter the market landscape. Most importantly, the report provides valuable insights into the pipeline products within the global allergic conjunctivitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current allergic conjunctivitis market is dominated by brands, generics and off-label formulations which have high patient affordability, and there is strong competition. The pipeline for allergic conjunctivitis lacks innovation and has 17 molecules in clinical development. Allergic conjunctivitis market has low unmet needs as the market is well served by the currently available different treatment options from different classes of therapies

Scope

The scope of the report includes:

• Annualized global allergic conjunctivitis market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report are the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across phases by mechanism of action, and the emerging trends. The key classes of mechanism of action include antihistamines/anti-allergic drugs which account for the largest share of the pipeline fallowed by immunosuppressants, NSAIDs, immunotherapy and PDE4 (Phosphodiesterase type 4) inhibitors.
• Analysis of the current and future market competition in the global allergic conjunctivitis market. The key market players covered are Novagali Pharma SA, Fovea Pharmaceuticals SA, Cytos Biotechnology AG and Ono Pharmaceutical Co. Ltd.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future allergic conjunctivitis market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global allergic conjunctivitis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global allergic conjunctivitis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global allergic conjunctivitis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Novagali Pharma S.A
Fovea Pharmaceuticals SA
Cytos Biotechnology AG
Ono Pharmaceutical Co. Ltd

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3184/Allergic-Conjunctivitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global hemophilia market was valued at $6.5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.

Scope

The scope of the report includes:

• Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.
• Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N.V., Novo Nordisk.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global haemophilia market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global haemophilia market landscape? – Identify, understand and capitalize.

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3183/Hemophilia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report offering, “Pneumonia – Drug Pipeline Analysis and Market Forecasts to 2016”. is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increases in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.

Scope

The scope of the report includes:

• Annualized global pneumonia market revenues data from 2000 to 2009, forecast for seven years to 2016.
• Key geographies covered in this report include the Unites States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action are cell wall synthesis inhibitors, protein synthesis inhibitors and topoisomerase II and topoisomerase IV inhibitors.
• Analysis of the current and future market competition in the global pneumonia market. The key market players covered are AstraZeneca, Pfizer, Bayer, GSK and J&J Pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future pneumonia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global pneumonia market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global pneumonia market landscape? – Identify, understand and capitalize.

Companies Mentioned

Forest Laboratories, Inc
Basilea Pharmaceutica
Advanced Life Sciences
Theravance, Inc

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3182/Pneumonia-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

GlobalData has released a pharmaceutical and healthcare report, “Hepatitis C – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hepatitis C market. The report identifies the key trends shaping and driving the global hepatitis C market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global hepatitis C market to grow at 9.8% annually for the next seven years to reach $8.5 billion by 2016. This growth is primarily attributed to high unmet need in the market which is expected to be served by strong pipeline candidates. The growth will be further supported by the prevalence of the disease. GlobalData has concluded that the global hepatitis C market is underserved by the current product options and so there is significant scope for new entrants to capture value from underserved segments. Designing products with curative properties, high safety profiles and better patient compliance is one of key challenges for this market and could provide a significant market share for any company.

Scope

The scope of the report includes:

• Annualized global hepatitis C market revenues data from 2000 to 2009, forecast for seven years to 2016.
• Key geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include protease inhibitors, polymerase inhibitors, toll receptor agonists, drugs with interferon-like actions, HCV inhibitors and immunomodulators.
• Analysis of the current and future market competition in the global hepatitis C market. The key market players covered are Merck, Human Genome Sciences, Novartis, Vertex, Janssen, Mitsubishi, Tibotec and Roche.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future hepatitis C market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis C market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global hepatitis C market landscape? – Identify, understand and capitalize.

Companies Mentioned

Merck & Co
F. Hoffmann-La Roche and Pharmasset
Human Genome Sciences and Novartis
Vertex Pharmaceuticals and Tibotec
Pharmaceuticals

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3181/Hepatitis-C-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

Pharmaceutical and healthcare report, “Stomach Cancer – Drug Pipeline Analysis and Market Forecasts to 2016”, is an essential source of information and analysis on the global stomach cancer market. The report identifies the key trends shaping and driving the global stomach cancer market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global stomach cancer segment.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global gastric cancer market is expected to value $1,313m in 2016. Most of the chemotherapies are already off-patent while Taxotere and Xeloda are expected to lose their patents during 2010 to 2011. Taxotere’s generic version, produced by Hospira, has already been approved in Europe through the decentralized procedure. The market is expected to be driven by the increase in demand due to the launch of promising targeted therapies currently in the late stage of development. The pending approval of Herceptin in the US and Japan will also boost the revenues generated in the gastric cancer market. However, the new therapies are not expected go off-patent before 2016. Therefore, the market is expected to witness strong growth in market revenues in the forecast period.

Scope

The scope of the report includes:

• Annualized global (gastrointestinal) stomach cancer market revenues data from 2001 to 2009, forecast for seven years to 2016.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data split across different phases by mechanism of action and emerging trends. The key classes of mechanism of action are mTOR inhibitors, PARP inhibitors, microtubule inhibitors, VEGFR inhibitors, multiple tyrosine kinase inhibitors, Heat Shock Protein 90 inhibitors, Eg5 inhibitors, Farnesyl-OH-transferase inhibitors, angiogenesis inhibitors and combinations of several existing chemotherapies.
• Analysis of the current and future competition in the global stomach cancer market. The key market players covered include GlaxoSmithKline, Novartis Pharmaceuticals, Merck & Co, Eli Lilly and Company, Amgen, Fresenius Biotech GmBH, ACT Biotech, Genta Incorporated and Bristol Myers-Squibb.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future stomach cancer market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global gastrointestinal (stomach) cancer market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global gastrointestinal (stomach) cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global gastrointestinal (stomach) cancer market landscape? – Identify, understand and capitalize.

Companies Mentioned

GlaxoSmithKline
Novartis Pharmaceuticals
Eli Lilly and Company
Merck & Co

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3180/Stomach-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-

The report provides detailed analysis and forecasts of the global wind power market and the Canada wind market in particular. It also helps in analyzing and forecasting key metrics relating to the installed capacities, market size and growth. The report facilitates to understand onshore and offshore market in Canada. It provides information relating to the major wind farms onshore and offshore projects and also the upcoming projects in Canada. The report helps to comprehend the wind turbine industry and the regulatory framework regarding the wind market in Canada. It offers interesting results on the market share of the top manufacturers in the Canada wind turbine industry. Additionally, it also provides ten profiles of the major wind turbine companies in Canada. The report also provides trends and analysis of investments in the Canada wind power market as well as deal summary and news flow for the last 6 months. On an all, it helps an investor to gauge the market and technological development of the Canada wind market.

Scope

• Canada Wind Market Overview, Market Size and Growth
• Predict and forecast future wind industry trends in Canada
• Review of the wind turbine market, wind farms etc
• Key policies and regulatory framework supporting the Canada Wind Market
• Identify growth segments and opportunities in the Canada Wind Industry
• Canada Wind Turbine Industry and the leading players in the Canadian wind market. Key companies covered include Enercon GmbH, Vestas Wind Systems A/S, GE Energy,Finavera Renewables Inc., Renewable Energy Systems Ltd, EarthFirst Canada Inc., Acciona Energia, S.A. and AIM PowerGen Corporation
• Key details regarding the active and upcoming wind projects in Canada

Reasons to buy

• Gain the most up to date and in-depth information on the Canada wind power market
• Analyzes the Canada Wind Turbine Industry
• Identify the key growth and investment opportunities within the Canada market based on the deal analysis
• Facilitate decision-making based on strong historic and forecast data, deal analysis and recent developments
• Develop strategies based on the latest operational and regulatory events in Canada
• Rapidly help to prepare more detailed and effective planning materials
• Understand and respond to your competitors’ business structure, strategy and prospects
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market
• Identify and analyze the strengths and weaknesses of the leading wind companies in Canada

Companies Mentioned

Enercon GmbH,
Vestas Wind Systems A/S,
GE Energy,
Finavera Renewables Inc.,
Renewable Energy Systems Ltd,
EarthFirst Canada Inc.,
Acciona Energia, S.A.,
AIM PowerGen Corporation,
Naturener, S.A.,
TransAlta Wind,
Canadian Hydro Developers,
EPCOR Power L.P.,

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/2542/Canada-Wind-Energy-Market-Analysis-and-Forecasts-to-2013.html
———————————————-

“The Future of High Potency Active Pharmaceutical Ingredients (HPAPIs), Market Forecasts and Growth Opportunities to 2015 – Growing Demand Drives Investment in Capacity”. The study, which is an offering from the company’s Chemicals Research Group, provides in-depth analysis of the global HPAPIs market with revenue forecasts up to 2015. Revenue forecasts, which include historical statistics of the market, are provided for the major regions – Europe, North America and Asia Pacific. The factors that drive and restrain the growth of the HPAPIs market are also analyzed in the report. In addition, the research provides market share analysis of the leading HPAPIs producers for major regions. The market for HPAPIs is also analyzed based on the product types and therapeutic applications at a global level. The report is built using the data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

Scope

- HPAPIs market revenues data from 2005 to 2009 and forecast for six years to 2015.
- HPAPIs in key regions – Europe, North America and Asia Pacific.
- Coverage of the product types and therapeutic applications of the global HPAPIs market.
- Drivers such as increasing demand due to the growth in better targeted drugs and restraints such as the economic recession for the global market as well as for the regional markets.
- Information on the competitive landscape with the revenue shares of the leading companies in the major regions of the world such as Sigma Aldrich, Bristol Myers Squibb, Sanofi Aventis, Carbogen Amcis and Novasep.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the global HPAPIs market.
- Design and develop your product development, marketing and sales strategies.
- Develop market-entry and market expansion strategies.
- Identify key companies best positioned to take advantage of the emerging market opportunities.
- Benchmark different geographies by the historic and forecasted growth of the HPAPIs market.
- Identify macro and micro-economic trends shaping and driving the global HPAPIs market.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1964/The-Future-of-High-Potency-Active-Pharmaceutical-Ingredients-HPAPIs-Market-Forecasts-and-Growth-Opportunities-to-2015-Growing-Demand-Drives-Investment-in-Capacity.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

“The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 – Increasing Prescription Rate to Drive Revenues”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the dermatology therapeutics market from 2001 to 2009, forecast forward to 2016
- Analysis of the leading therapeutic segments. These include Acne, Psoriasis, Dermatitis, Rosacea and Skin diseases.
- Analysis of the dermatology therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the dermatology therapeutics market including market size, annual cost of therapy, and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, GlaxoSmithKline, Leo Pharma, Sanofi-Aventis, Genentech, Novartis AG, Johnson & Johnson, Galderma Pharma SA, and Merck & Co, Inc.
- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global dermatology therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Companies Mentioned

GlaxoSmithKline plc (GSK)
Johnson & Johnson
Bayer AG
Merck & Co., Inc
Novartis AG
Sanofi-Aventis
LEO Pharma A/S
F. Hoffmann-La Roche Ltd
L’Oreal
Galderma S.A
Nestle S.A.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1962/The-Future-of-Dermatology-Therapeutics-Analysis-and-Market-Forecasts-to-2016-Increasing-Prescription-Rate-to-Drive-Revenues.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

“The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 – Increasing Generic Competition Creates Challenges”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global pain management therapeutics market. The report analyzes the markets for pain management in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
- Annualized market data for the pain management market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including neuropathic pain, osteoarthritis, cancer pain, migraine and fibromyalgia.
- Analysis of the pain management market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the pain management market including market size, the annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in the various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Inc., Eli Lilly and Company, Johnson & Johnson, Novartis AG, Merck & Co Inc., and Cephalon, Inc.
- Key M&A activities that have taken place in 2009 and the licensing agreements in the 2008-2009 global pain management market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Companies Mentioned

Pfizer, Inc.
Eli Lilly and Company
Johnson & Johnson
Endo Pharmaceuticals
Novartis AG
Merck & Co Inc
Cephalon, Inc.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1961/The-Future-of-Pain-Management-Therapeutics-Analysis-and-Market-Forecasts-to-2016-Increasing-Generic-Competition-Creates-Challenges.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com